Flu Hunters: House Committee Searches For Pandemic Plan
Update to 2005 outline of US response to pandemic influenza was due at the end of 2016, but has yet to be released.
You may also be interested in...
AnaptysBio, Jounce and ObsEva were the first three companies to go public in 2017 – all in January – while no therapeutics firms went public in January 2016. The difference? Better US biopharma stock performance.
Uncertainty about US FDA's direction under the new president may have spurred staff to ensure views on several issues released before administration changed.
Beyond pricing, industry experts weigh in on how the next administration has shifted expectations across a range of areas – including tax reform, FDA standards and the Cancer Moonshot Initiative.